GBA1变异帕金森病患者丘脑底核深部脑刺激后的纵向认知功能临床与生物学决定因素
本研究匹配比较携带GBA1变异的帕金森病患者接受与未接受丘脑底核深部脑刺激(STN-DBS)的认知下降轨迹,发现STN-DBS未加速认知下降(3年MoCA差值-0.72分,p=0.583),痴呆转化风险与GBA1状态、基线MoCA<26及年龄>69岁相关。
要点
- GBA1变异携带者接受STN-DBS未加速认知下降。
- 痴呆转化风险与GBA1状态、基线MoCA<26及年龄>69岁相关。
- GBA1携带者视空间/执行域评分<4/5预测痴呆。
核心结论
- 符合一般STN-DBS适应证的GBA1变异携带者接受DBS后未出现加速认知下降。
- 探索性痴呆预测因素可辅助DBS候选者的咨询。
研究设计与样本
- 匹配队列研究,携带GBA1变异伴STN-DBS组28例,不伴DBS组28例。
- 另设非携带者伴STN-DBS组40例,不伴DBS组43例。
- 分析临床、遗传及脑脊液生物标志物(Aβ1-42、h-Tau、p181-Tau、神经丝轻链),用MoCA评估认知,线性混合模型估计认知斜率。
主要发现
- PDGBA1+DBS+与PDGBA1+DBS-认知下降无显著差异(-0.24 MoCA分/年,95%CI -1.11至0.70),3年随访预计-0.72分(p=0.583)。
- PDGBA1+DBS+与PDGBA1+DBS-痴呆转化风险无差异(HR=0.55,95%CI 0.23-1.34,p=0.119)。
- PDGBA1-DBS+与PDGBA1-DBS-痴呆转化风险无差异(HR=1.22,95%CI 0.53-2.83,p=0.897)。
- 痴呆风险与GBA1状态(HR=3.04,95%CI 1.05-8.79,p=0.041)、基线MoCA<26(HR=3.05,95%CI 1.29-7.21,p=0.011)、基线年龄>69岁(HR=4.42,95%CI 1.79-10.89,p=0.001)相关。
- GBA1携带者视空间/执行域评分<4/5预测痴呆(HR=4.71,95%CI 1.25-17.86,p=0.022)。
关键数值与推荐
- 3年随访最小可检测斜率差异为1.33 MoCA分。
- 痴呆转化分析以MoCA<21为起点进行Kaplan-Meier分析。
临床怎么用
- GBA1变异携带者符合一般STN-DBS适应证时可考虑手术,未显示加速认知下降。
- 术前可评估GBA1状态、基线MoCA、年龄及视空间/执行功能以辅助痴呆风险咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN-DBS) remains controversial. Clarifying long-term cognitive outcomes is essential for informed decision making. METHODS: We assembled matched cohorts of patients carrying GBA1 variants with STN-DBS (PDGBA1+DBS+, n = 28) and without (PDG BA1+DBS-, n = 28). Additional cohorts included non-carriers with STN-DBS (PDGBA1-DBS+, n = 40) and without (PDGBA1-DBS-, n = 43). Clinical, genetic, and cerebrospinal fluid (CSF) biomarkers (Aβ1-42, h-Tau, p181-Tau, and neurofilament light chain) were analyzed. Cognition was assessed using the Montreal Cognitive Assessment (MoCA). Cognitive slopes were estimated using linear mixed models and the minimally detectable slope difference at 3-year follow-up was 1.33 MoCA points enabling sensitivity to clinically meaningful changes. Secondarily, conversion to dementia was analyzed with Kaplan-Meier-analysis once the MoCA was < 21. RESULTS: There was no significant difference in cognitive decline between PDGBA1+DBS+ and PDGBA1+DBS- (-0.24 MoCA points/year; 95% confidence interval [CI] = -1.11 to 0.70) projecting to -0.72 MoCA points at 3-year-follow-up (p = 0.583). Secondarily, the risk for conversion to dementia did not differ between PDGBA1+DBS+ and PDGBA1+DBS- (HR = 0.55, 95% CI = 0.23-1.34, p = 0.119) or between PDGBA1-DBS+ and PDGBA1-DBS- (HR = 1.22, 95% CI = 0.53-2.83, p = 0.897). Dementia risk was associated with GBA1 status (HR = 3.04, 95% CI = 1.05-8.79, p = 0.041), baseline MoCA < 26 (HR = 3.05, 95% CI = 1.29-7.21, p = 0.011), and baseline age > 69 years (HR = 4.42, 95% CI = 1.79-10.89, p = 0.001). In GBA1 carriers, a visuospatial/executive domain score < 4/5 predicted dementia (HR = 4.71, 95% CI = 1.25-17.86, p = 0.022). INTERPRETATION: GBA1 variant carriers meeting general STN-DBS indication criteria did not show accelerated cognitive decline in the presence of STN-DBS. In addition, exploratory predictors of dementia could support counseling of DBS candidates. ANN NEUROL 2026;99:976-988.
引用
- Loeffler MA, Klocke P, Wurster I, et al. Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation. Ann Neurol. 2026. PMID: 41542740. doi:10.1002/ana.78139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。